文献速递胃肠外科围术期管理与 ERAS

抗反流术后质子泵抑制剂管理:继续或停药?前肠外科专家调查

To wean or not to wean: proton pump inhibitor management after anti-reflux surgery amongst foregut experts.
PubMed 文献 · Surg Endosc · 2024-06-06

该调查旨在了解美国前肠外科和胃肠病学专家对抗反流手术后质子泵抑制剂(PPI)停用或减量的实践模式。121名受访者中42%术后立即停用PPI,58%选择减量(46%始终减量,47%选择性减量),92%在术后3个月内减量。仅19%的决策基于医学文献,多数基于个人偏好或既往培训。

要点

  • 抗反流术后PPI管理存在两种主要模式:42%立即停药,58%减量。
  • 92%的减量者在术后3个月内完成减量,仅19%的决策基于循证医学。
  • 决策主要受个人偏好(42%)和既往培训(39%)影响,缺乏高质量证据。

核心结论

  • 抗反流术后PPI停用方案主要有立即停药和逐渐减量两种,近半数医生立即停药,略多于半数医生选择减量。
  • 这些决策主要基于个人偏好和既往培训,而非循证医学证据,提示需要制定循证推荐。

研究设计与样本

  • 通过电子调查工具(Qualtrics XM)匿名发放问卷,为期三个月,调查美国前肠外科和胃肠病学专家对抗反流术后PPI管理的实践和观点。
  • 调查共回收121份回复,其中111名(92%)为外科医生。

主要发现

  • 50名(42%)受访者总是在抗反流术后立即停用PPI。
  • 剩余70名(58%)中,46%总是减量,47%选择性减量;92%的减量者在术后3个月内完成减量。
  • 5名受访者从不停止PPI。
  • 仅23名(19%)的决策基于医学文献或循证医学,42%(n=50)基于个人偏好,39%(n=47)基于既往培训。

临床怎么用

  • 临床医生应了解当前抗反流术后PPI管理缺乏统一循证方案,实践差异大。
  • 可参考多数专家在术后3个月内减量PPI的做法,但需结合患者具体情况个体化决策。

局限性

  • 调查回复率较低(121/644,约19%),可能存在选择偏倚。
  • 调查依赖自我报告,未与客观临床数据核实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most patients undergoing anti-reflux surgery (ARS) have a history of preoperative proton pump inhibitor (PPI) use. It is well-established that ARS is effective in restoring the anti-reflux barrier, eliminating the ongoing need for costly PPIs. Current literature lacks objective evidence supporting an optimal postoperative PPI cessation or weaning strategy, leading to wide practice variations. We sought to objectively gauge current practice and opinion surrounding the postoperative management of PPIs among expert foregut surgeons and gastroenterologists in the United States. METHODS: We created a survey of postoperative PPI management protocols, with an emphasis on discontinuation and timing of PPI cessation, and aimed to determine what factors played a role in the decision-making. An electronic survey tool (Qualtrics XM, Qualtrics, Provo, UT) was used to distribute the survey and to record the responses anonymously for a period of three months. RESULTS: The survey was viewed 2658 times by 373 institutions and shared with 644 members. In total, 121 respondents participated in the survey and 111 were surgeons (92%). Fifty respondents (42%) always discontinue PPIs immediately after ARS. Of the remaining 70 respondents (58%), 46% always wean or taper PPIs postoperatively and 47% wean or taper them selectively. The majority (92%) of practitioners taper within a 3-month period postoperatively. Five respondents never discontinue PPIs after ARS. Overall, only 23 respondents (19%) stated their protocol is based on medical literature or evidence-based medicine. Instead, decision-making is primarily based on anecdotal evidence/personal preference (42%, n = 50) or prior training/mentors (39%, n = 47). CONCLUSIONS: There are two major protocols used for PPI discontinuation after ARS: Nearly half of providers abruptly stop PPIs, while just over half gradually tapers them, most often in the early postoperative period. These decisions are primarily driven by institutional practices and personal preferences, underscoring the need for evidence-based recommendations.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Pflüger MJ, Coker AM, Zosa BM, et al. To wean or not to wean: proton pump inhibitor management after anti-reflux surgery amongst foregut experts. Surg Endosc. 2024. PMID: 38844731. doi:10.1007/s00464-024-10910-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。